Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

Details for Australian Patent Application No. 2003270824 (hide)

Owner The United States of America, as represented by The Secretary of the Department of Health and Human Services

Inventors Collins, Peter L.; Skiadopoulos, Mario H.; Murphy, Brian R.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2003270824

PCT Number PCT/US03/29685

PCT Pub. Number WO2004/027037

Priority 60/412,053 18.09.02 US

Filing date 18 September 2003

Wipo publication date 8 April 2004

Acceptance publication date 19 February 2009

International Classifications

A61K 39/155 (2006.01) Medicinal preparations containing antigens or antibodies - Paramyxoviridae, e.g. parainfluenza virus

C07K 14/115 (2006.01) Peptides having more than 20 amino acids

C07K 14/135 (2006.01) Peptides having more than 20 amino acids

C12N 7/04 (2006.01) Viruses, e.g. bacteriophages - Inactivation or attenuation

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

Event Publications

15 January 2004 Complete Application Filed

  Priority application(s): 60/412,053 18.09.02 US

20 May 2004 Application Open to Public Inspection

  Published as AU-B-2003270824

19 February 2009 Application Accepted

  Published as AU-B-2003270824

18 June 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003270825-PROCESS OF MAKING FLUORINATED ALCOHOLS

2003270823-CANCER IMMUNOTHERAPY WITH A VIRAL ANTIGEN-DEFINED, IMMUNOMODULATOR-SECRETING CELL VACCINE